Citation Impact
Citing Papers
Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis
2005
Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response
2013 StandoutNobel
Recognition of Borrelia burgdorferi , the Lyme Disease Spirochete, by TLR7 and TLR9 Induces a Type I IFN Response by Human Immune Cells
2009
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study
2021 Standout
Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register
2009
Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)
2008
In situ click chemistry generation of cyclooxygenase-2 inhibitors
2017 Standout
Cyclooxygenase Isozymes: The Biology of Prostaglandin Synthesis and Inhibition
2004 Standout
Shared and distinct mechanisms of fibrosis
2019
The economics of treatment in early rheumatoid arthritis
2009
A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis
2007
Systemic sclerosis-associated interstitial lung disease
2020
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006 Standout
Therapeutic potential of resveratrol: the in vivo evidence
2006 Standout
Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2
2007
Myasthenia Gravis
2016 Standout
Psoriasis
2009 Standout
Reduced Risk of Upper Gastrointestinal Ulcer Complications With Celecoxib, A Novel Cox-2 Inhibitor
2000
Rheumatoid arthritis
2016 Standout
Pathogenesis and clinical features of psoriasis
2007 Standout
Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis
2013
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
2008 Standout
Current risk factors for work disability associated with rheumatoid arthritis: Recent data from a US national cohort
2009
Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point
2015
Evidence that anti–tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report
2005
The problem of choice: current biologic agents and future prospects in RA
2013
Neutrophil Apoptosis: Relevance to the Innate Immune Response and Inflammatory Disease
2010
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
2005
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Ustekinumab: Lessons Learned from Targeting Interleukin‐12/23p40 in Immune‐Mediated Diseases
2009
Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria
2006 StandoutNobel
Systemic sclerosis
2017 Standout
The REDCap consortium: Building an international community of software platform partners
2019 Standout
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
2009
Psoriasis
2021 Standout
Psoriasis: Which therapy for which patient
2018
Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response
2007
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial
2006
Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience
2007
IL-6 as a keystone cytokine in health and disease
2015 Standout
Intracellular Toll-like Receptors
2010 StandoutNobel
Neutrophils in the activation and regulation of innate and adaptive immunity
2011 Standout
Adalimumab for long‐term treatment of psoriatic arthritis: Forty‐eight week data from the adalimumab effectiveness in psoriatic arthritis trial
2007
Clinical management of psoriatic arthritis
2018
Classification and diagnostic criteria for psoriatic arthritis
2005
Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study
2009
Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?
2005
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
2000 Standout
Crohn's disease
2016 Standout
Ankylosing spondylitis
2007 Standout
Inflammatory Bowel Disease
2002 Standout
Drug repurposing: progress, challenges and recommendations
2018 Standout
Psoriatic arthritis assessment tools in clinical trials
2005
Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial
2006
Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy
2014 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Abandoned therapies and unpublished trials in rheumatoid arthritis
2003
Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial
2006
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
2013 Standout
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Rheumatoid arthritis
2010 Standout
A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease
2000
PD-1 and PD-1 ligands: from discovery to clinical application
2007
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
2009
Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double‐blind, placebo‐controlled study
2006
The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study
2007
Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty‐two–week open‐label trial
2006
Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell–mediated spontaneous autoimmune arthritis in mice
2004 StandoutNobel
Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept
2008
Treatment recommendations for psoriatic arthritis
2008
Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register
2007
Major lung complications of systemic sclerosis
2018
Cytokines in the pathogenesis of rheumatoid arthritis
2007 Standout
T-cell-targeted therapies in rheumatoid arthritis
2006
The PASE questionnaire: Pilot-testing a Psoriatic Arthritis Screening and Evaluation tool
2007
Plaque thickness and morphology in psoriasis vulgaris associated with therapeutic response
2009
Inflammation and p53: A Tale of Two Stresses
2011
The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder
2006
Borrelia burgdorferi–Infected, Interleukin‐6–Deficient Mice Have Decreased Th2 Responses and Increased Lyme Arthritis
1998
Host–pathogen interactions promoting inflammatory Lyme arthritis: use of mouse models for dissection of disease processes
2001
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
2019
Advances in pathogenesis and treatment of systemic sclerosis
2015
Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial
2015
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
2005
Systemic sclerosis
2015
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies
2006 Standout
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
2013 StandoutNobel
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Dispensable roles of Gsdmd and Ripk3 in sustaining IL-1β production and chronic inflammation in Th17-mediated autoimmune arthritis
2021 StandoutNobel
p53 and the Carcinogenicity of Chronic Inflammation
2016
Nrf2 activation improves experimental rheumatoid arthritis
2023 StandoutNobel
Autologous hematopoietic stem cell transplantation has better outcomes than conventional therapies in patients with rapidly progressive systemic sclerosis
2016
Conventional systemic agents for psoriasis. A systematic review.
2006
Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review.
2006
The Bcl-2 Family Antagonist ABT-737 Significantly Inhibits Multiple Animal Models of Autoimmunity
2009
Sustained Clinical Response and High Infliximab Survival in Psoriatic Arthritis Patients: A 3-year Long-Term Study
2007
Toll-Like Receptors
2003 Standout
Therapies for dactylitis in psoriatic arthritis. A systematic review.
2006
Clinical Research Informatics: Survey of Recent Advances and Trends in a Maturing Field
2013
Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience
2007
PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
2014 Standout
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.
2007
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Oxidative Stress: An Essential Factor in the Pathogenesis of Gastrointestinal Mucosal Diseases
2014 Standout
JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines
2015
Toll-Like Receptor 2 Is Required for Innate, But Not Acquired, Host Defense to Borrelia burgdorferi
2002
Extracting research-quality phenotypes from electronic health records to support precision medicine
2015
Clinical and Histopathological Features of Patients with Systemic Sclerosis Undergoing Endomyocardial Biopsy
2015
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell–mediated spontaneous autoimmune arthritis in mice
2004 StandoutNobel
Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation
2016
Phospholipase A2Enzymes: Physical Structure, Biological Function, Disease Implication, Chemical Inhibition, and Therapeutic Intervention
2011 Standout
Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation
2008
Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis
2020 StandoutNobel
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
2020 Standout
PD-1 and Its Ligands in Tolerance and Immunity
2008 Standout
Works of Eric Ruderman being referenced
Anti-interleukin-6 therapy in rheumatoid arthritis.
2010
Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study
2004
Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
2005
Histologic liver abnormalities in an autopsy series of patients with rheumatoid arthritis
1997
Systematic review of studies of productivity loss due to rheumatoid arthritis
2005
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
2005
Evaluation and management of psoriatic arthritis: the role of biologic therapy
2003
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double‐blind, active drug–controlled study
2008
Incorporating the Treat-to-Target Concept in Rheumatoid Arthritis
2012
Treatment of Osteoarthritis with a Once-Daily Dosing Regimen of Celecoxib: A Randomized, Controlled Trial
2000
The CDK domain of p21 is a suppressor of IL‐1β‐mediated inflammation in activated macrophages
2009
Drug Insight: abatacept for the treatment of rheumatoid arthritis
2006
Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
2005
Early Murine Lyme Carditis Has a Macrophage Predominance and Is Independent of Major Histocompatibility Complex Class Ii-Cd4+ T Cell Interactions
1995
Intracellular signal pathways: Potential for therapies
2009
The treatment of psoriasis and psoriatic arthritis: An interdisciplinary approach
2006
Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist
2004
Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial
2011
Safety of biologic therapy in rheumatoid arthritis
2011
Portability of an algorithm to identify rheumatoid arthritis in electronic health records
2012
Synovial tissue response to treatment with campath‐1h
1995
Psoriasis and Psoriatic Arthritis
2005
Novel TNF antagonists for the treatment of rheumatoid arthritis
2009
The role of concomitant methotrexate in biologic therapy for rheumatoid arthritis.
2013